IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report

Abstract

Background Following the strong recommendation for coronavirus disease 2019 (COVID‑19) vaccination, many patients with medical comorbidities are being immunized. However, the safety of vaccination in patients with autoimmune diseases has not been well established. We report a new case of biopsy-proven IgA vasculitis with nephritis presenting as a nephrotic syndrome after mRNA COVID-19 vaccination in a patient with a history of leukocytoclastic vasculitis. Case presentation A 76-year-old man with a history of cutaneous leukocytoclastic vasculitis presented with purpura in both lower limbs, followed by nephrotic syndrome after the second dose of BNT162b2 mRNA COVID-19 vaccination. Skin and renal biopsy revealed IgA vasculitis with nephritis. The patient’s past medical history of leukocytoclastic vasculitis and features of chronicity in renal pathology suggest an acute exacerbation of preexisting IgA vasculitis after COVID-19 vaccination. After the steroid and renin-angiotensin system inhibitor use, purpura and acute kidney injury recovered within a month. Subnephrotic proteinuria with microscopic hematuria remained upon follow-up. Conclusion Physicians should keep in mind the potential (re)activation of IgA vasculitis following mRNA COVID-19 vaccines. It is important to closely monitor COVID-19 vaccinated patients, particularly those with autoimmune diseases.

Immunoglobulin A Vasculitis With Intussusception in Children

“…Among the 85 articles initially identified, we found 13 cases with relatively complete clinical information. [5][6][7][8][9][10][11][12][13][14][15][16][17] The patients' ages reported in the literature ranged from 3 to 14 years, with an average age of 6.6 years (Table 3). There were 10 boys (76.9%) and 3 girls (23.1%).…”

Type I IFN in Glomerular Disease: Scarring beyond the STING

“…However, we should consider that the activation of this class of TLRs could be the consequence of previous IFN-I or other pathway activation and/or as a result of actions carried out by any number of immune cell types, rather than directly by cells within the glomerulus. Interestingly, some RNA-based prophylactics and therapeutics have been associated with altered kidney function [ 90 , 91 , 92 ], suggesting that these exogenous nucleic acids could be implicated in the induction of the IFN-I pathway. On the other hand, there is also experimental evidence pointing to the advantages of RNA-based drugs that target coding and non-coding RNAs associated with the development of kidney disease [ 93 , 94 ].…”